COX7A2 (cytochrome c oxidase subunit 7A2) is a nuclear-encoded component of cytochrome c oxidase (Complex IV), the terminal enzyme of the mitochondrial electron transport chain. As part of the respiratory chain, COX7A2 participates in transferring electrons from cytochrome c to molecular oxygen, enabling the reduction of oxygen to water and generating the electrochemical gradient necessary for oxidative phosphorylation and ATP synthesis 1. The protein plays a regulatory role in complex IV assembly and function within the context of respiratory chain supercomplexes that organize electron flux 2. Clinically, COX7A2 expression levels correlate with disease outcomes across multiple conditions. In glioma patients, high COX7A2 expression independently predicted longer overall survival and better prognosis 1, while in Barrett's adenocarcinoma, elevated COX7A2 correlated with poor prognosis 3. Conversely, abundant COX7A2 and other oxidative phosphorylation proteins are associated with preserved cognitive function in dementia patients, with reduced levels present in Alzheimer's disease and Lewy body dementias 4. During COVID-19 infection, COX7A2 expression is significantly altered, reflecting compensatory upregulation in response to viral-induced mitochondrial dysfunction that persists for weeks post-infection 5. Additionally, COX7A2 is targeted by artemisinin in anaplastic thyroid cancer cells 6, and COX7A2 knockout mice display novel phenotypes relevant to rare disease research 7.